March 1, 2017 – Results from a new prospective clinical trial indicate that high-dose-rate (HDR) brachytherapy administered in a single, 19 Gray (Gy) treatment may be a safe and effective alternative to longer courses of HDR treatment for men with localized prostate cancer. ...continue reading "Single High Dose of Brachytherapy Radiation May Be Safe and Effective for Localized Prostate Cancer"
A small randomized Phase II study for men with progressive castrate-resistant prostate cancer has tested the effects of taking one-fourth the standard dose of Zytiga (abiraterone acetate) after a low-fat breakfast instead of standard dose on an empty stomach.
Taking one-fourth the standard dose with a low-fat breakfast, the study found, can be as effective – and four times less expensive – as taking the standard dose as recommended: on an empty stomach. The finding has significant financial implications.
Abiraterone acetate is a standard treatment for metastatic CRPC. Retail cost is about $8000 per month.
A group of doctors led by Russell Szmulewitz, MD, assistant professor of medicine at the University of Chicago and a specialist in medical treatment of patients with advanced prostate cancer, observed that "despite a large food effect (about a 17-fold increase in CMax with a high-fat meal), abiraterone acetate was administered under fasting conditions in its pivotal trials." ...continue reading "Low-dose Zytiga (abiraterone acetate) with a low-fat breakfast as effective as full dose on an empty stomach, study finds"
On December 18, 2015 President Obama signed into law a bill re-authorizing the James Zadroga 9/11 Health and Compensation Act of 2010, to extend the September 11th Victim Compensation Fund (“VCF”) for an additional five years.
This will benefit individuals impacted by the events of 9/11 including men who developed prostate cancer as a result of exposure to the disaster.
Importantly, the re-authorization extends the deadline for submitting claims. Previously the VCF said it would stop receiving claims on October 3, 2016. This is no longer the case. As of September 2, the new deadline for filing a claim (and all supporting documents) is December 18, 2020.
Full story in our blog.
Cancer cells' genetic pathways show which patients are likely to develop aggressive types of the disease
Sept. 7, 2016 -- Scientists at Cedars-Sinai have developed a new way to identify which prostate cancer patients are likely to develop aggressive types of the disease even if their tumors at first appear to be lower risk. The new findings could help physicians prescribe the most effective treatments for each patient based on how genes are activated in the individual tumor.
These findings raise the possibility that by determining the gene expression profile of a patient's tumor, physicians may be able to identify aggressive disease at the outset of diagnosis and start treatment earlier," said Sungyong You, PhD, an instructor in the Cedars-Sinai Department of Surgery and the first author of the study.
...continue reading "New tumor analysis method identifies high-risk prostate cancer"
Sept. 6, 2016 – Digital rectal exam, the dreaded finger exam to check for prostate cancer, used to be a mainstay of check-ups for older men. With its value now in question, some doctors share the risks and benefits with their patients and let them decide. So, should they or shouldn’t they?
“The evidence suggests that in most cases, it is time to abandon the digital rectal exam (DRE),” said Ryan Terlecki, M.D., a Wake Forest Baptist urologist who recently published an article on the topic in Current Medical Research and Opinion. “Our findings will likely be welcomed by patients and doctors alike.”
Terlecki said the DRE, referred to by some urologists as a “clinical relic,” subjects a large number of men to invasive, potentially uncomfortable examinations for relatively minimal gain. In addition, it may deter some men from undergoing any test for prostate cancer. ...continue reading "Digital Rectal Exam To Detect Prostate Cancer Usually Unnecessary, Study Finds"
September 6, 2016. A study by investigators at Brigham and Women's Hospital (BWH) finds that a rise in prostate-specific antigen (PSA) levels in healthy men who have previously been treated for prostate cancer is significantly associated with a 1.6-fold increased risk of death. The team also studied men with prostate cancer who had another illness such as a history of heart attack or stroke, and did not find that PSA failure was predictive of the risk of death in these men.
The new work suggests that it's especially important for healthy men to be given information about the early results of available clinical trials that have been shown to reduce PSA failure, according to the study's authors. ...continue reading "PSA failure predicts risk of death only in healthy men"
Indications for Prostate Biopsy
|Digital Rectal Exam (DRE)
suspicious for cancer at any PSA level
|PSA above 3 ng/mL||High Risk of prostate cancer based on multiple risk factors.|
|TRUS (transrectal ultrasound) Guided Biopsy. In some circumstances, Doppler ultrasound- guided or MRI-guided biopsy may be preferred or required.||If TRUS-guided-biopsy not done, follow up in 6 to 12 months with PSA/DRE. Consider testing FPSA, PHI, and/or PCA3 if PSA is between 3 and 10 ng/mL.||Measure free PSA (FPSA), PHI (Prostate Health Index), or PCA3 in patients with PSA 3 - 10 ng/mL|
June 8, 2015. BUFFALO, N.Y. — A study led by University of Buffalo and Roswell Park Cancer Institute researchers claims to have identified beliefs and personality traits associated with higher levels of distress in newly diagnosed prostate cancer patients. The study's authors say their findings support the value of emotional and informational support for patients and perhaps early counseling for some who are the most distressed. ...continue reading "Prostate Cancer Diagnosis Calls for Early Support So That Men Can Make Smart Treatment Decisions, Study Says"